Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

  • Sort by:
  • Browse by:
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 50 of 93
SINGLE VASCULAR CELL HETEROGENEITY IN HEALTH AND DISEASE: A COVID-19 UPDATE   (ABSTRACT 49)
Peter Carmeliet
VIB KU Leuven Center for Cancer Biology, Leuven, Belgium
from CROI 2021 on March 9, 2021 12:00 AM-12:00 AM
BODY ON FIRE: MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN   (ABSTRACT 50)
Elizabeth A Whittaker
Imperial College Healthcare NHS Trust, London, United Kingdom
from CROI 2021 on March 9, 2021 12:00 AM-12:00 AM
THINK ABOUT IT: NEUROLOGIC MANIFESTATIONS OF COVID-19   (ABSTRACT 51)
Benedict D Michael
University of Liverpool, Liverpool, United Kingdom
from CROI 2021 on March 9, 2021 12:00 AM-12:00 AM
COVID-19: CONCERNS OF THE HEART   (ABSTRACT 52)
Valentina O Puntmann
Goethe University, University Hospital Frankfurt, Frankfurt, Germany
from CROI 2021 on March 9, 2021 12:00 AM-12:00 AM
HOW TO GENERATE GOOD KILLERS BY INITIATING ART (NOT TOO) EARLY?   (ABSTRACT 42)
Lydie Trautmann
Vaccine and Gene Therapy Institute, Beaverton, OR, USA
from CROI 2021 on March 9, 2021 12:00 AM-12:00 AM
BREAKING THE B-CELL FOLLICLE BARRIER TO ELIMINATE VIRAL RESERVOIRS   (ABSTRACT 43)
Afam Okoye
Oregon Health & Science University, Beaverton, OR, USA
from CROI 2021 on March 9, 2021 12:00 AM-12:00 AM
INTRINSIC RESISTANCE OF RESERVOIR CELLS TO IMMUNE KILLING   (ABSTRACT 41)
R. Brad Jones
Weill Cornell Medicine, New York, NY, USA
from CROI 2021 on March 9, 2021 12:00 AM-12:00 AM
TYPE I INTERFERON RESISTANCE OF REBOUND HIV-1   (ABSTRACT 44)
Beatrice H Hahn
University of Pennsylvania, Philadelphia, PA, USA
from CROI 2021 on March 9, 2021 12:00 AM-12:00 AM
TRIPLE DRUG ART, DUAL ART, OR JUST ART?   (ABSTRACT 45)
Jose R Arribas
Hospital Universitario La Paz, Madrid, Spain
from CROI 2021 on March 9, 2021 12:00 AM-12:00 AM
NOVEL ANTIRETROVIRAL THERAPIES IN CLINICAL DEVELOPMENT   (ABSTRACT 46)
Alexandra L Calmy
Geneva University Hospitals, Geneva, Switzerland
from CROI 2021 on March 9, 2021 12:00 AM-12:00 AM
ARVS AND ART FOR NEWBORNS AND INFANTS: A LAST FRONTIER   (ABSTRACT 47)
Moherndran Archary
University of KwaZulu-Natal, Durban, South Africa
from CROI 2021 on March 9, 2021 12:00 AM-12:00 AM
GOT ANYTHING FOR THIS COUGH? NEW ANTIVIRALS FOR TREATMENT OF SARS-COV-2   (ABSTRACT 48)
Davey M Smith
University of California San Diego, San Diego, CA, USA
from CROI 2021 on March 9, 2021 12:00 AM-12:00 AM
YOUNG WOMEN: ADHERENCE, EFFECT, AND RETENTION   (ABSTRACT 53)
Thesla Palanee-Phillips
Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
from CROI 2021 on March 9, 2021 12:00 AM-12:00 AM
CHALLENGES AND OPPORTUNITIES IN IMPLEMENTING PREP IN KEY POPULATIONS   (ABSTRACT 54)
Greg A Millett
amfAR, District of Columbia, DC, USA
from CROI 2021 on March 9, 2021 12:00 AM-12:00 AM
MODELS OF DELIVERING PREP IN EAST AFRICA: INNOVATIONS AND LESSONS LEARNED   (ABSTRACT 55)
Moses R Kamya
Department of Medicine, Makerere University, Kampala, Uganda
from CROI 2021 on March 9, 2021 12:00 AM-12:00 AM
INCORPORATING INJECTABLE PREP AND NEWER FORMULATIONS INTO LMIC   (ABSTRACT 56)
Yogan Pillay
Clinton Health Access Initiative, Pretoria, South Africa
from CROI 2021 on March 9, 2021 12:00 AM-12:00 AM
WELCOME AND DAILY ROADMAP
Elaine J Abrams
Columbia University, New York, NY, USA
from CROI 2021 on March 9, 2021 10:00 AM-11:00 AM
HIV-1 BNABS: LOOKING AHEAD   (ABSTRACT 36)
Marina Caskey
The Rockefeller University, New York, NY, USA
Peter W Hunt
University of California San Francisco, San Francisco, CA, USA
from CROI 2021 on March 9, 2021 10:00 AM-11:00 AM
SUSTAINED DELIVERY AND LONG-ACTING AGENTS FOR PREVENTION OF HIV   (ABSTRACT 37)
Linda-Gail Bekker
Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa
Sharon L. Hillier
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
from CROI 2021 on March 9, 2021 10:00 AM-11:00 AM
INTRODUCTION OF SPEAKERS (PART I)
Susan P Buchbinder
San Francisco Department of Public Health, San Francisco, CA, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
PHYLOGENETIC ANALYSIS OF THE TIMING OF SARS-COV-2 INTRODUCTIONS INTO WASHINGTON STATE   (ABSTRACT 138)
Diana M Tordoff
University of Washington, Seattle, WA, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
FROM TESTING TO MORTALITY: COVID-19 AND THE INVERSE CARE LAW IN SWITZERLAND   (ABSTRACT 139)
Julien Riou
University of Bern, Bern, Switzerland
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
SEX/GENDER DIFFERENCES IN TESTING, PRESENTATION, AND OUTCOMES OF SARS-COV-2 INFECTION   (ABSTRACT 140)
Eileen P Scully
Johns Hopkins University, Baltimore, MD, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
RACIAL DISPARITIES IN COVID-19 POSITIVITY AMONG PEOPLE LIVING WITH HIV IN THE US   (ABSTRACT 141)
Jessica Y Islam
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
LIVE QUESTIONS AND ANSWERS (PART I) WITH PRESENTERS AND ATTENDEES
Diana M Tordoff
University of Washington, Seattle, WA, USA
Susan P Buchbinder
San Francisco Department of Public Health, San Francisco, CA, USA
Julien Riou
University of Bern, Bern, Switzerland
Eileen P Scully
Johns Hopkins University, Baltimore, MD, USA
Jessica Y Islam
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
INTRODUCTION OF SPEAKERS (PART II)
James McIntyre
Anova Health Institute, Johannesburg, South Africa
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
HIV AND COVID-19 INPATIENT OUTCOMES: A MATCHED RETROSPECTIVE MULTICENTRE ANALYSIS   (ABSTRACT 142)
Ming Jie Lee
Chelsea and Westminster Hospital National Health Service Foundation Trust, London, United Kingdom
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
CHANGES IN HIV TESTING SERVICES AFTER COVID-19 IN 11 SUB-SAHARAN AFRICAN COUNTRIES   (ABSTRACT 143)
Bakary Drammeh
Centers for Disease Control and Prevention, Atlanta, GA, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
DRAMATIC DECLINE IN PUBLIC SECTOR HIV/STI TESTING DURING SARS-COV-2 PANDEMIC, OREGON   (ABSTRACT 144)
Timothy William Menza
Oregon Health Authority, Portland, OR, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
COVID-19 IMPACT ON INDEX TESTING SERVICES IN 5 HIGH HIV PREVALENCE INDIAN DISTRICTS   (ABSTRACT 145)
Ajay K.R. Enugu
Johns Hopkins University, Hyderabad, India
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
LIVE QUESTIONS AND ANSWERS (PART II) WITH PRESENTERS AND ATTENDEES
Ming Jie Lee
Chelsea and Westminster Hospital National Health Service Foundation Trust, London, United Kingdom
James McIntyre
Anova Health Institute, Johannesburg, South Africa
Bakary Drammeh
Centers for Disease Control and Prevention, Atlanta, GA, USA
Timothy William Menza
Oregon Health Authority, Portland, OR, USA
Ajay K.R. Enugu
Johns Hopkins University, Hyderabad, India
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
INTRODUCTION OF SPEAKERS (PART I)
Joseph J Eron
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND MORTALITY IN NURSING-HOME SETTING   (ABSTRACT 121)
Myron S Cohen
The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
BAMLANIVIMAB+ETESEVIMAB FOR TREATMENT OF COVID-19 IN HIGH-RISK AMBULATORY PATIENTS   (ABSTRACT 122)
Michael Dougan
Massachusetts General Hospital, Boston, MA, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
CASIRIVIMAB WITH IMDEVIMAB ANTIBODY COCKTAIL FOR COVID-19 PREVENTION: INTERIM RESULTS   (ABSTRACT 123)
Meagan P. O'Brien
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
POTENT NEUTRALIZING ANTIBODIES FOR SEVERE COVID-19: A RANDOMIZED CLINICAL TRIAL   (ABSTRACT 124)
Carlijn Jordans
Erasmus Medical Center, Rotterdam, Netherlands
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
LIVE QUESTIONS AND ANSWERS (PART I) WITH PRESENTERS AND ATTENDEES
Myron S Cohen
The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Joseph J Eron
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Michael Dougan
Massachusetts General Hospital, Boston, MA, USA
Meagan P. O'Brien
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
Carlijn Jordans
Erasmus Medical Center, Rotterdam, Netherlands
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
INTRODUCTION OF SPEAKERS (PART II)
Douglas D Richman
University of California San Diego, La Jolla, CA, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
ESTIMATING WITHIN-HOST R0 FOR SARS-COV-2 AND IMPLICATIONS FOR ANTIVIRAL THERAPY   (ABSTRACT 125)
Ruian Ke
Los Alamos National Laboratory, Los Alamos, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
PHASE IIA PROOF-OF-CONCEPT TRIAL OF NEXT-GENERATION MATURATION INHIBITOR GSK3640254   (ABSTRACT 126)
Christoph Spinner
Technical University of Munich School of Medicine, Munich, Germany
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH   (ABSTRACT 127)
Sorana Segal-Maurer
New York-Presbyterian Queens, Flushing, NY, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
ACTIVITY AND RESISTANCE CHARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR   (ABSTRACT 128)
Laurie VanderVeen
Gilead Sciences, Inc, Foster City, CA, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
RESISTANCE PROFILE OF MK-8507, A NOVEL NNRTI SUITABLE FOR WEEKLY ORAL HIV TREATMENT   (ABSTRACT 129)
Tracy Lauren Diamond
Merck & Co, Inc, West Point, PA, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
LIVE QUESTIONS AND ANSWERS (PART II) WITH PRESENTERS AND ATTENDEES
Ruian Ke
Los Alamos National Laboratory, Los Alamos, USA
Douglas D Richman
University of California San Diego, La Jolla, CA, USA
Christoph Spinner
Technical University of Munich School of Medicine, Munich, Germany
Sorana Segal-Maurer
New York-Presbyterian Queens, Flushing, NY, USA
Laurie VanderVeen
Gilead Sciences, Inc, Foster City, CA, USA
Tracy Lauren Diamond
Merck & Co, Inc, West Point, PA, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
INTRODUCTION OF SPEAKERS (PART I)
Raphael J Landovitz
University of California Los Angeles, Los Angeles, CA, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
IMPACT OF VAGINAL STIS ON BNAB PROTECTION IN MACAQUES   (ABSTRACT 146)
David A Garber
Centers for Disease Control and Prevention, Atlanta, GA, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
PHASE 1 PK, SAFETY, AND ACCEPTABILITY STUDY OF 3-MONTH DAPIVIRINE VAGINAL RINGS   (ABSTRACT 147)
Albert Liu
San Francisco Department of Public Health, San Francisco, CA, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
INCIDENCE OF HIV INFECTION WITH DAILY OR ON-DEMAND ORAL PREP WITH TDF/FTC IN FRANCE   (ABSTRACT 148)
Jean-Michel Molina
University of Paris, Paris, France
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
IMPACT OF COMMON SIDE EFFECTS ON PREP PERSISTENCE DURING PREGNANCY IN SOUTH AFRICA   (ABSTRACT 149)
Dvora L Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
LIVE QUESTIONS AND ANSWERS (PART I) WITH PRESENTERS AND ATTENDEES
David A Garber
Centers for Disease Control and Prevention, Atlanta, GA, USA
Raphael J Landovitz
University of California Los Angeles, Los Angeles, CA, USA
Albert Liu
San Francisco Department of Public Health, San Francisco, CA, USA
Jean-Michel Molina
University of Paris, Paris, France
Dvora L Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
from CROI 2021 on March 9, 2021 11:15 AM-1:15 PM
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 50 of 93